PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24142642-0	2013	Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis.	Platinum	124-132	methylenetetrahydrofolate reductase	Homo sapiens	13-48	
24142642-1	2013	PURPOSE: Methylenetetrahydrofolate reductase (MTHFR) has been implicated in lung cancer risk and response to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).	Platinum	109-117	methylenetetrahydrofolate reductase	Homo sapiens	9-44	
24142642-1	2013	PURPOSE: Methylenetetrahydrofolate reductase (MTHFR) has been implicated in lung cancer risk and response to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).	Platinum	109-117	methylenetetrahydrofolate reductase	Homo sapiens	46-51	
24142642-3	2013	We performed meta-analysis to investigate the effect of MTHFR C677T polymorphism on lung cancer risk and response to platinum-based chemotherapy in advanced NSCLC.	Platinum	117-125	methylenetetrahydrofolate reductase	Homo sapiens	56-61	
24142642-11	2013	In addition, MTHFR 677TT homozygote carriers had a better response to platinum-based chemotherapy in advanced NSCLC in the recessive model.	Platinum	70-78	methylenetetrahydrofolate reductase	Homo sapiens	13-18	
24142642-12	2013	CONCLUSION: The MTHFR C677T polymorphism might be a genetic marker for lung cancer risk or response to platinum- based chemotherapy in advanced NSCLC.	Platinum	103-111	methylenetetrahydrofolate reductase	Homo sapiens	16-21